<DOC>
	<DOCNO>NCT02462499</DOCNO>
	<brief_summary>The aim study determine efficacy safety treatment drug eplerenone patient chronic central serous chorioretinopathy .</brief_summary>
	<brief_title>Eplerenone Treatment Chronic Central Serous Chorioretinopathy Hungarian Population</brief_title>
	<detailed_description />
	<mesh_term>Central Serous Chorioretinopathy</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Chronic central serous chorioretinopathy ( CSCR ) persistent subretinal fluid OCT 3 month initial presentation . Written inform consent Persons impair decisionmaking ability . Pregnant woman actively try conceive . Additional eye disease affect macula posterior retina . Creatinine clearance &lt; 50 ml/min Hyperkalemia &gt; 5 mmol/l Serum creatinine &gt; 2 mg/dl men &gt; 1.8 mg/dl woman Treatment potassium spar agent potassium Treatment drug know cause interaction eplerenone Microalbuminuria patient type 2 diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>